Filing Flows › Spruce Biosciences (SPRB) › Q4 2024
Spruce Biosciences (SPRB) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Apr 15, 2025
Spruce Biosciences (SPRB) reported revenue of $697K for the fourth quarter 2024 (Q4 2024), -76% from a year earlier and +16% from the quarter before.
Spruce Biosciences, Q4 2024: revenue $697K (-76% year over year), net loss $23.6M, operating cash flow −$20.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $697K | +16% | -76% |
| Operating profit | −$24.1M | — | — |
| Net earnings | −$23.6M | — | — |
| Operating cash flow | −$20.7M | — | — |
What changed
Revenue was $697K in Q4 2024, down 76% year over year and up 16% from the previous quarter.
Operating costs exceeded revenue by $24.1M, an operating margin of -3453.9%. Total costs grew 76% against a revenue fall of 76%. The fastest-growing cost line was Research & development (+93%). The quarter ended with a net loss of $23.6M, wider than the previous quarter's $8.7M loss.
Operating cash flow was −$20.7M. Non-cash charges added back $9K of depreciation and amortization and $1.0M of share-based compensation. Working capital and other items added $1.9M.
Questions
What was Spruce Biosciences' revenue in the fourth quarter 2024?
Spruce Biosciences (SPRB) reported revenue of $697K for the fourth quarter 2024 (Q4 2024), -76% from a year earlier and +16% from the quarter before.
Source: Spruce Biosciences 10-K on SEC EDGAR.